Navigation Links
UT Southwestern plastic surgeons deploy new carbon dioxide-based fractional laser
Date:2/12/2008

ents or that we plan on removing so we can determine what effect its going to have before we start treating patients clinically.

With more than 200 lasers on hand for various procedures, UT Southwestern is one of the worlds leaders in providing patients with laser treatment options. This latest model, made by California-based Lumenous Device Technologies, has a large arm and two heads and can be used on a variety of conditions, including wrinkle removal, acne scarring, alleviating dark pigmentation, and other conditions that the plastic surgery group is investigating.

Early carbon dioxide-based lasers were popular in the early 1990s, but faded from favor due to long recovery periods sometimes spanning several months and pigmentation inequities that resulted in loss of pigmentation in the patients skin after treatment.

The new laser treatments are office-based procedures done on an out-patient basis, but may require some local or regional anesthetic, with recovery time related to the type of procedure. In most instances recovery is between three and five days. Depending on whats required, procedure costs can range from $500 to $3,000 and are usually considered cosmetic.

The popularity of out-patient, office-based laser procedures has been rising as lasers have improved.

There are a lot of patients who would rather not have surgery and who are looking for things to improve their appearance without surgical down time, Dr. Kenkel said. In addition, theres a whole group of younger patients who are looking for improvement who are not necessarily in need of surgery but perhaps would benefit from some of the lesser invasive procedures that we have to offer.

Americans spent more than $12 billion last year on cosmetic procedures, involving 11.5 million surgical and nonsurgical procedures, according to the American Society for Aesthetic Plastic Surgery. Nonsurgical procedures, which include laser treatments, accounted fo
'/>"/>

Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
2. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
3. UT Southwestern scientist receives NIH Directors New Innovator Award
4. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
5. 2 UT Southwestern researchers elected to National Academy of Sciences Institute of Medicine
6. UT Southwestern researcher named Howard Hughes Medical Institute investigator
7. UT Southwestern urologist uses Botox to treat debilitating condition
8. Physicians seek to improve the quality of sleep in ICU, researchers at UT Southwestern report
9. UT Southwestern: Patients with mild Cushing syndrome may benefit from adrenalectomy
10. BMI criteria for obesity surgery should be lowered, UT Southwestern researchers suggest
11. Water Picks Up Odor From Plastic Pipes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT Southwestern plastic surgeons deploy new carbon dioxide-based fractional laser
UT Southwestern plastic surgeons deploy new carbon dioxide-based fractional laser
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Cambodia 3A World AIDS Day HIV Campaign Testing Millions to Again Launch During Cambodias National Water Festival 60453 1Cambodia 3A World AIDS Day HIV Campaign Testing Millions to Again Launch During Cambodias National Water Festival 60453 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 1Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 3NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform 60444 1NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform 60444 2NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform 60444 3